Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study. 1987

W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
Tulane University Medical Center, New Orleans, LA.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D003953 Diagnosis-Related Groups A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system. Case Mix,DRG,Diagnosis Related Group,Diagnosis-Related Group,Case Mixes,DRGs,Diagnostic-Related Group,Group, Diagnostic-Related,Groups, Diagnostic-Related,Diagnosis Related Groups,Diagnostic Related Group,Diagnostic-Related Groups,Group, Diagnosis Related,Group, Diagnosis-Related,Group, Diagnostic Related,Groups, Diagnosis Related,Groups, Diagnosis-Related,Groups, Diagnostic Related,Related Group, Diagnosis,Related Groups, Diagnosis
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001388 Aziridines Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms. Ethyleneimines,Azacyclopropanes, Saturated,Dimethyleneimines,Saturated Azacyclopropanes

Related Publications

W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
November 1991, Investigational new drugs,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
November 1985, Cancer treatment reports,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
January 1994, Investigational new drugs,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
June 1991, Anti-cancer drugs,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
February 2002, Investigational new drugs,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
July 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
December 1987, Cancer treatment reports,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
November 1990, Journal of the National Cancer Institute,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
May 1990, Investigational new drugs,
W J Stuckey, and J Crowley, and L H Baker, and N R Larrimer, and K H Hanson, and J D Bonnet, and L A White
February 1989, American journal of clinical oncology,
Copied contents to your clipboard!